Celeste Leigh Pearce

List of Publications by Year
in descending order

137 papers	9,955 citations	66250 44 h-index	43601 95 g-index
139 all docs	139 docs citations	139 times ranked	14180 citing authors

#	Article	IF	Citations
1	The Association of Prenatal Vitamins and Folic Acid Supplement Intake with Odds of Autism Spectrum Disorder in a High-Risk Sibling Cohort, the Early Autism Risk Longitudinal Investigation (EARLI). Journal of Autism and Developmental Disorders, 2022, 52, 2801-2811.	1.7	7
2	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
3	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
4	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	1.1	1
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
6	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Network Open, 2022, 5, e2147343.	2.8	41
7	Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma. Gynecologic Oncology, 2022, 165, 552-559.	0.6	4
8	Abstract CT208: Feasibility, acceptability, and evaluation of a self-care app to enhance purposeful living among ovarian cancer patients (NCT04458168). Cancer Research, 2022, 82, CT208-CT208.	0.4	0
9	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
10	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	1.5	26
11	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8
12	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 927-935.	1.1	10
13	Abstract 794: Trends of ovarian cancer incidence by histotype and race/ethnicity in the U.S.: 1992-2017. , 2021, , .		0
14	Acupressure for Cancer-fatigue in Ovarian Cancer Survivor (AcuOva) Study: A community-based clinical trial study protocol examining the impact of self-acupressure on persistent cancer-related fatigue in ovarian cancer survivors. Contemporary Clinical Trials, 2021, 107, 106477.	0.8	8
15	Phenotype risk scores (PheRS) for pancreatic cancer using time-stamped electronic health record data: Discovery and validation in two large biobanks. Journal of Biomedical Informatics, 2021, 113, 103652.	2.5	15
16	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, 2021, , .	0.6	5
17	Identification of novel epithelial ovarian cancer loci in women of African ancestry. International Journal of Cancer, 2020, 146, 2987-2998.	2.3	18
18	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 caseâ€“control studies. European Journal of Epidemiology, 2020, 35, 1025-1042.	2.5	2

#	Article	IF	Citations
19	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	1.2	12
20	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
21	Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology, 2020, 6, e200421.	3.4	78
22	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
23	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	5.8	75
24	The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. Pathology, 2020, 52, S30-S31.	0.3	0
25	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
26	â€œI am not a statisticâ€•ovarian cancer survivorsâ€™ views of factors that influenced their long-term survival. Gynecologic Oncology, 2019, 155, 461-467.	0.6	19
27	Association Between Life Purpose and Mortality Among US Adults Older Than 50 Years. JAMA Network Open, 2019, 2, e194270.	2.8	115
28	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	0.9	22
29	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	12.8	35
30	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
31	Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 996-999.	1.1	19
32	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	0.8	16
33	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecologic Oncology, 2019, 153, 343-355.	0.6	28
34	A comprehensive geneâ€“environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	2.3	12
35	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
36	Ovarian cancer risk, <scp>ALDH</scp>2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. Cancer Science, 2018, 109, 435-445.	1.7	10

#	Article	IF	Citations
37	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal of Epidemiology, 2018, 47, 460-472.	0.9	33
38	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	1.6	8
39	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 395-404.	1.1	33
40	Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. International Journal of Cancer, 2018, 142, 460-469.	2.3	6
41	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	1.1	20
42	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
43	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
44	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
45	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
46	Ovarian cancer: density equalizing mapping of the global research architecture. International Journal of Health Geographics, 2017, 16, 3.	1.2	28
47	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
48	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
49	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 116-125.	1.1	6
50	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. American Journal of Epidemiology, 2017, 185, 8-20.	1.6	61
51	Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012. Journal of the National Cancer Institute, 2017, 109, .	3.0	18
52	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	1.1	10
53	Timing of births and oral contraceptive use influences ovarian cancer risk. International Journal of Cancer, 2017, 141, 2392-2399.	2.3	22
54	The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. American Journal of Obstetrics and Gynecology, 2017, 216, 270.e1-270.e9.	0.7	55

#	Article	IF	Citations
55	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
56	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nature Reviews Cancer, 2017, 17, 65-74.	12.8	235
57	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
58	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics and Gynecology, 2016, 127, 828-836.	1.2	39
59	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
60	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	1.1	32
61	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
62	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
63	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal of Cancer, 2016, 139, 2646-2654.	2.3	7
64	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
65	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
66	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
67	Assessment of Multifactor Geneâ€“Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
68	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
69	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
70	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
71	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
72	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5

#	Article	IF	Citations
73	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13
74	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	0.8	7
75	African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1094-1100.	1.1	33
76	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
77	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
78	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
79	Expression of Wnt-Signaling Pathway Genes and Wnt-Target Genes in Human Endometriosis Tissue [25]. Obstetrics and Gynecology, 2015, 125, 18S.	1.2	1
80	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
81	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
82	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
83	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
84	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	1.9	26
85	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
86	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
87	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
88	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	1.1	82
89	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
90	Variation in NF-Îºb Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13

#	Article	IF	Citations
91	Risk of Ovarian Cancer and the NF-Î²B Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.4	48
92	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€“Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
93	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
94	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
95	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
96	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
97	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€“control studies. Cancer Causes and Control, 2013, 24, 989-1004.	0.8	84
98	Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research, 2013, 6, 811-821.	0.7	77
99	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	1.1	54
100	Antiretroviral-Treated HIV-Infected Women Have Similar Long-Term Kidney Function Trajectories as HIV-Uninfected Women. AIDS Research and Human Retroviruses, 2013, 29, 755-760.	0.5	3
101	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	1.6	169
102	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
103	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	0.9	146
104	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
105	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
106	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of caseâ€“control studies. Lancet Oncology, The, 2012, 13, 385-394.	5.1	753
107	Endometriosis and ovarian cancer â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e190.	5.1	0
108	Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Research and Treatment, 2012, 132, 653-660.	1.1	10

#	Article	IF	Citations
109	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertility and Sterility, 2011, 95, 40-45.	0.5	20
110	Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer. PLoS ONE, 2011, 6, e28141.	1.1	65
111	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	1.4	22
112	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031.	1.1	0
113	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
114	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	1.1	21
115	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
116	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
117	Polymorphism in the GALNT1 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 600-604.	1.1	23
118	Genetic Variation in TYMS in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1822-1830.	1.1	24
119	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility â€œHot-Spotâ€• PLoS Genetics, 2010, 6, e1001016.	1.5	48
120	ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 245-250.	1.1	75
121	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	1.4	42
122	Markers of inflammation and risk of ovarian cancer in Los Angeles County. International Journal of Cancer, 2009, 124, 1409-1415.	2.3	100
123	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	2.3	59
124	Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer, 2009, 115, 531-539.	2.0	97
125	Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Research and Treatment, 2009, 118, 161-168.	1.1	34
126	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276

#	Article	IF	Citations
127	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	2.3	73
128	The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. Clinical Cancer Research, 2008, 14, 5833-5839.	3.2	32
129	BRCA1 variants in a family study of African-American and Latina women. Human Genetics, 2005, 116, 497-506.	1.8	24
130	Determination of Sequence Variation and Haplotype Structure for the Gonadotropin-Releasing Hormone (GnRH) and GnRH Receptor Genes: Investigation of Role in Pubertal Timing. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1091-1099.	1.8	52
131	Clarifying the PROGINS Allele Association in Ovarian and Breast Cancer Risk: A Haplotype-Based Analysis. Journal of the National Cancer Institute, 2005, 97, 51-59.	3.0	62
132	Systematic Evaluation of Genetic Variation at the Androgen Receptor Locus and Risk of Prostate Cancer in a Multiethnic Cohort Study. American Journal of Human Genetics, 2005, 76, 82-90.	2.6	72
133	Prevention of cancers of the breast, endometrium and ovary. Oncogene, 2004, 23, 6379-6391.	2.6	130
134	Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertility and Sterility, 2004, 82, 186-195.	0.5	122
135	Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genetics, 2003, 33, 177-182.	9.4	1,818
136	Modeling and E-M Estimation of Haplotype-Specific Relative Risks from Genotype Data for a Case-Control Study of Unrelated Individuals. Human Heredity, 2003, 55, 179-190.	0.4	249
137	Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intra-Uterine Contraceptive System. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0